Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim
Guggenheim lowered the firm’s price target on Nautilus Biotechnology (NAUT) to $2.50 from $4 and keeps a Buy rating on the shares. A key area ...
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial ...